An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Clinical trial NCT02225574 · TERMINATED
Trial details
- NCT number
- NCT02225574
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-11
- Primary completion
- 2017-02-02
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.